HK1218549A1 - 新型抗體框架 - Google Patents

新型抗體框架

Info

Publication number
HK1218549A1
HK1218549A1 HK16106054.2A HK16106054A HK1218549A1 HK 1218549 A1 HK1218549 A1 HK 1218549A1 HK 16106054 A HK16106054 A HK 16106054A HK 1218549 A1 HK1218549 A1 HK 1218549A1
Authority
HK
Hong Kong
Prior art keywords
novel antibody
antibody frameworks
frameworks
novel
antibody
Prior art date
Application number
HK16106054.2A
Other languages
English (en)
Inventor
Sebastian Meyer
David Urech
Original Assignee
Numab Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Numab Ag filed Critical Numab Ag
Publication of HK1218549A1 publication Critical patent/HK1218549A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1068—Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
HK16106054.2A 2013-06-26 2016-05-27 新型抗體框架 HK1218549A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13003264 2013-06-26
PCT/EP2014/001730 WO2014206561A1 (en) 2013-06-26 2014-06-26 Novel antibody frameworks

Publications (1)

Publication Number Publication Date
HK1218549A1 true HK1218549A1 (zh) 2017-02-24

Family

ID=48699516

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16106054.2A HK1218549A1 (zh) 2013-06-26 2016-05-27 新型抗體框架

Country Status (12)

Country Link
US (3) US10174102B2 (zh)
EP (1) EP3013864A1 (zh)
JP (4) JP6708544B2 (zh)
KR (4) KR102286053B1 (zh)
CN (2) CN113943366A (zh)
AU (2) AU2014301629B2 (zh)
CA (1) CA2914829A1 (zh)
HK (1) HK1218549A1 (zh)
IL (3) IL243311B (zh)
NZ (1) NZ714320A (zh)
SG (2) SG10201811017QA (zh)
WO (1) WO2014206561A1 (zh)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3013864A1 (en) 2013-06-26 2016-05-04 Numab AG Novel antibody frameworks
CN107922486B (zh) 2015-06-15 2022-05-31 努玛治疗有限公司 异源二聚体多特异性抗体形式
ES2903408T3 (es) 2016-02-25 2022-04-01 Cell Medica Switzerland Ag Miembros de unión para PD-L1
CN109071649B (zh) 2016-03-17 2021-10-01 努玛创新有限公司 抗TNFα抗体及其功能片段
DK3219726T3 (da) 2016-03-17 2020-12-07 Tillotts Pharma Ag Anti-TNF-alfa-antistoffer og funktionelle fragmenter deraf
PL3219727T3 (pl) 2016-03-17 2021-05-17 Tillotts Pharma Ag Przeciwciała anty-TNF alfa i ich funkcjonalne fragmenty
EP3430044A1 (en) 2016-03-17 2019-01-23 Numab Innovation AG Anti-tnf alpha -antibodies and functional fragments thereof
EA039323B1 (ru) 2016-03-17 2022-01-13 Нумаб Инновейшн Аг Антитела к фно и их функциональные фрагменты
GB201621591D0 (en) * 2016-12-19 2017-02-01 Ucb Biopharma Sprl Antibody molecules and method
KR20200015505A (ko) * 2017-06-05 2020-02-12 누맙 세러퓨틱스 아게 신규 항 hsa 항체
WO2018224439A1 (en) 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-hsa antibodies
CN110719918B (zh) 2017-06-05 2024-05-24 努玛治疗有限公司 靶向至少cd3和hsa的异源二聚体多特异性抗体形式
WO2018224441A1 (en) 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
CN116199785A (zh) 2017-06-25 2023-06-02 西雅图免疫公司 多特异性抗体及其制备和使用方法
AU2018295119A1 (en) * 2017-06-25 2020-02-06 Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. Multi-specific antibodies and methods of making and using thereof
EP3459968A1 (en) * 2017-09-20 2019-03-27 Numab Innovation AG Novel stable antibody variable domain framework combinations
WO2020157305A1 (en) 2019-01-31 2020-08-06 Numab Therapeutics AG Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
WO2022147338A1 (en) * 2020-12-30 2022-07-07 Ascendo Biotechnology, Inc. Monoclonal antibody against human mac-1 and uses thereof
JP2024508736A (ja) 2021-02-12 2024-02-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 補体ｃ３抗原結合タンパク質
WO2024098026A2 (en) * 2022-11-04 2024-05-10 Mink Therapeutics, Inc. B-cell maturation antigen (bcma) chimeric antigen receptor invariant natural killer t cells and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
CN100415765C (zh) 2003-08-07 2008-09-03 宜康公司 兔单克隆抗体的人源化方法
WO2008004834A1 (en) 2006-07-06 2008-01-10 Isu Abxis Co., Ltd Humanized monoclonal antibody highly binding to epidermal growth factor receptor, egf receptor
FR2910896B1 (fr) * 2006-12-29 2012-11-16 Lab Francais Du Fractionnement Anticorps monoclonal dirige contre le recepteur humain des ldl
TWI501976B (zh) 2007-05-21 2015-10-01 Alder Biopharmaceuticals Inc 抗ＴＮＦ－α之抗體及其用途
SI2158315T1 (sl) 2007-06-25 2016-05-31 Esbatech, An Alcon Biomedical Research Unit Llc Postopki za spreminjanje protiteles in spremenjena protitelesa z izboljšanimi funkcionalnimi lastnostmi
PL2307454T3 (pl) 2008-06-25 2017-07-31 Esbatech, An Alcon Biomedical Research Unit Llc Trwałe i rozpuszczalne przeciwciała hamujące VEGF
ES2687259T5 (es) * 2008-06-25 2022-10-14 Novartis Ag Anticuerpos estables y solubles que inhiben TNF
KR101956059B1 (ko) * 2008-06-25 2019-03-08 에스바테크 - 어 노바티스 컴파니 엘엘씨 보편적 항체 프레임워크를 사용한 래빗 항체의 인간화
US8193235B2 (en) 2009-06-12 2012-06-05 University Of Kansas Compositions and methods for establishing and maintaining stem cells in an undifferentiated state
WO2011137362A1 (en) * 2010-04-30 2011-11-03 Rother Russell P Antibodies having reduced immunogenicity in a human
WO2012163519A1 (en) * 2011-05-27 2012-12-06 Dutalys Antibodies with improved folding stability
EP3013864A1 (en) 2013-06-26 2016-05-04 Numab AG Novel antibody frameworks
EP3459968A1 (en) * 2017-09-20 2019-03-27 Numab Innovation AG Novel stable antibody variable domain framework combinations

Also Published As

Publication number Publication date
AU2014301629A1 (en) 2015-12-10
SG10201811017QA (en) 2019-01-30
CN105579472B (zh) 2021-10-22
US20160130326A1 (en) 2016-05-12
EP3013864A1 (en) 2016-05-04
KR20220029763A (ko) 2022-03-08
IL313351A (en) 2024-08-01
CA2914829A1 (en) 2014-12-31
IL243311B (en) 2022-07-01
US20230212265A1 (en) 2023-07-06
KR20240000622A (ko) 2024-01-02
KR20160024923A (ko) 2016-03-07
AU2014301629B2 (en) 2020-02-06
WO2014206561A1 (en) 2014-12-31
AU2020202770A1 (en) 2020-05-14
US11427628B2 (en) 2022-08-30
KR102286053B1 (ko) 2021-08-04
SG11201509899PA (en) 2016-01-28
CN113943366A (zh) 2022-01-18
AU2020202770B2 (en) 2023-01-05
NZ714320A (en) 2022-02-25
JP2024026176A (ja) 2024-02-28
KR20210097829A (ko) 2021-08-09
US10174102B2 (en) 2019-01-08
IL293477B1 (en) 2024-07-01
IL293477A (en) 2022-08-01
WO2014206561A8 (en) 2016-02-18
JP6708544B2 (ja) 2020-06-10
JP2019201643A (ja) 2019-11-28
US20190119359A1 (en) 2019-04-25
CN105579472A (zh) 2016-05-11
IL243311A0 (en) 2016-03-31
JP2022028659A (ja) 2022-02-16
JP2016523537A (ja) 2016-08-12

Similar Documents

Publication Publication Date Title
IL269528A (en) Anti- FCRH5 antibodies
HK1218549A1 (zh) 新型抗體框架
HK1217023A1 (zh) 新型抗體
GB201322583D0 (en) Antibodies
EP2968553A4 (en) ANTIBODY FORMULATIONS
HK1220142A1 (zh) 抗體
GB201308658D0 (en) Antibodies
GB201315486D0 (en) Antibodies
GB201300706D0 (en) Antibody
IL245488A0 (en) Anti- ccl17 antibodies
GB201312226D0 (en) Improved antibodies
GB201318283D0 (en) Antibodies